AR066972A1 - Derivados azapeptidicos - Google Patents

Derivados azapeptidicos

Info

Publication number
AR066972A1
AR066972A1 ARP080102501A ARP080102501A AR066972A1 AR 066972 A1 AR066972 A1 AR 066972A1 AR P080102501 A ARP080102501 A AR P080102501A AR P080102501 A ARP080102501 A AR P080102501A AR 066972 A1 AR066972 A1 AR 066972A1
Authority
AR
Argentina
Prior art keywords
azapeptidic
derivatives
pharmaceutically acceptable
compound
azapeptides
Prior art date
Application number
ARP080102501A
Other languages
English (en)
Spanish (es)
Inventor
Roger D Tung
Scout L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of AR066972A1 publication Critical patent/AR066972A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
ARP080102501A 2007-06-12 2008-06-12 Derivados azapeptidicos AR066972A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29

Publications (1)

Publication Number Publication Date
AR066972A1 true AR066972A1 (es) 2009-09-23

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102501A AR066972A1 (es) 2007-06-12 2008-06-12 Derivados azapeptidicos

Country Status (25)

Country Link
US (4) US20090036357A1 (cg-RX-API-DMAC7.html)
EP (3) EP2322509B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010529196A (cg-RX-API-DMAC7.html)
KR (2) KR20120029480A (cg-RX-API-DMAC7.html)
CN (2) CN102424668A (cg-RX-API-DMAC7.html)
AR (1) AR066972A1 (cg-RX-API-DMAC7.html)
AT (2) ATE536343T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008267048C1 (cg-RX-API-DMAC7.html)
BR (2) BRPI0813911A2 (cg-RX-API-DMAC7.html)
CA (1) CA2692028C (cg-RX-API-DMAC7.html)
CO (1) CO6241121A2 (cg-RX-API-DMAC7.html)
CY (1) CY1109766T1 (cg-RX-API-DMAC7.html)
DE (1) DE602008000255D1 (cg-RX-API-DMAC7.html)
DK (1) DK2003120T3 (cg-RX-API-DMAC7.html)
ES (3) ES2394952T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100065T1 (cg-RX-API-DMAC7.html)
MX (1) MX2009013565A (cg-RX-API-DMAC7.html)
PL (1) PL2003120T3 (cg-RX-API-DMAC7.html)
PT (1) PT2003120E (cg-RX-API-DMAC7.html)
RS (1) RS51226B (cg-RX-API-DMAC7.html)
RU (2) RU2448958C2 (cg-RX-API-DMAC7.html)
SI (1) SI2003120T1 (cg-RX-API-DMAC7.html)
TW (1) TW200908970A (cg-RX-API-DMAC7.html)
WO (1) WO2008156632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200909079B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
CA2784530C (en) 2009-12-21 2018-05-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
HUE030883T2 (en) 2011-06-20 2017-06-28 H Lundbeck As Deuterated 1-piperazino-3-phenylindanes for the treatment of schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
MX374931B (es) * 2015-12-02 2025-03-06 Merck Sharp & Dohme Llc Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
KR102558066B1 (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
IL273579B2 (en) 2017-09-27 2025-10-01 Incyte Corp Salts of pyrrolizidine derivatives used as Tm inhibitors.
HRP20250676T1 (hr) 2018-06-29 2025-08-01 Incyte Corporation Formulacije inhibitora axl/mer
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
CN115697343A (zh) 2020-03-06 2023-02-03 因赛特公司 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
EP4135740A4 (en) * 2020-04-16 2024-05-22 The Medical College of Wisconsin, Inc. AEROSOLATED FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY TRACT REFLUX
CN114426568B (zh) * 2022-01-11 2023-04-25 嘉兴安谛康生物科技有限公司 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途
WO2024249517A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206497B1 (en) 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ES2189721T3 (es) 1992-12-29 2003-07-16 Abbott Lab Inhibidores de proteasa retroviral.
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
PL366998A1 (en) 2001-05-03 2005-02-07 F.Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
JP2005501880A (ja) 2001-08-31 2005-01-20 ブリストル−マイヤーズ スクイブ カンパニー Hiv療法におけるアタザナビルの使用
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
CN101829327A (zh) 2003-02-21 2010-09-15 加罗配方公司 包含喹啉抗疟化合物和蛋白酶抑制剂的组合的药物组合物及其应用
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US7718633B2 (en) 2004-07-06 2010-05-18 Abbott Laboratories Prodrugs of HIV protease inhibitors
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CA2588466A1 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+,k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
ES2394952T3 (es) 2007-06-12 2013-02-07 Concert Pharmaceuticals Inc. Derivados de axapéptido como inhibidores de la proteasa VIH
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
US8258309B2 (en) 2012-09-04
DK2003120T3 (da) 2010-03-15
CN101711237A (zh) 2010-05-19
ATE536343T1 (de) 2011-12-15
PL2003120T3 (pl) 2010-04-30
KR101185899B1 (ko) 2012-09-27
EP2116532B1 (en) 2011-12-07
HK1127345A1 (en) 2009-09-25
US20130041156A1 (en) 2013-02-14
ES2395137T3 (es) 2013-02-08
WO2008156632A1 (en) 2008-12-24
CA2692028A1 (en) 2008-12-24
AU2008267048A1 (en) 2008-12-24
HRP20100065T1 (hr) 2010-03-31
DE602008000255D1 (de) 2009-12-17
BRPI0813911A2 (pt) 2012-02-22
KR20120029480A (ko) 2012-03-26
ES2356334T3 (es) 2011-04-07
US20090036357A1 (en) 2009-02-05
RS51226B (sr) 2010-12-31
AU2008267048C1 (en) 2013-01-17
EP2116532A1 (en) 2009-11-11
KR20100020033A (ko) 2010-02-19
EP2003120A1 (en) 2008-12-17
MX2009013565A (es) 2010-06-02
RU2448958C2 (ru) 2012-04-27
BRPI0823520A2 (pt) 2013-12-17
EP2003120B1 (en) 2009-11-04
PT2003120E (pt) 2010-02-11
ZA200909079B (en) 2011-05-25
RU2010100821A (ru) 2011-07-20
CA2692028C (en) 2013-06-04
SI2003120T1 (sl) 2010-03-31
US20120165288A1 (en) 2012-06-28
US8158805B2 (en) 2012-04-17
TW200908970A (en) 2009-03-01
CN102424668A (zh) 2012-04-25
CN101711237B (zh) 2013-08-07
AU2008267048B2 (en) 2012-05-31
EP2322509A1 (en) 2011-05-18
RU2012101881A (ru) 2013-07-27
EP2322509B1 (en) 2012-08-22
EP2003120B9 (en) 2010-06-02
CO6241121A2 (es) 2011-01-20
JP2010529196A (ja) 2010-08-26
ATE447554T1 (de) 2009-11-15
HK1136576A1 (en) 2010-07-02
US20110009355A1 (en) 2011-01-13
CY1109766T1 (el) 2014-09-10
ES2394952T3 (es) 2013-02-07

Similar Documents

Publication Publication Date Title
AR066972A1 (es) Derivados azapeptidicos
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR057874A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DOP2012000128A (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
ECSP088257A (es) Derivados de amida
MX2025010799A (es) Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a)

Legal Events

Date Code Title Description
FB Suspension of granting procedure